Annals for Hospitalists Inpatient Notes - Sodium–Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction—What Hospitalists Need to Know
Authors: Sarah K. Adie, Matthew C. Konerman
Journal: Annals of Internal Medicine (2023)

Web ExclusivesApril 2023Annals for Hospitalists Inpatient Notes - Sodium–Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction—What Hospitalists Need to KnowSarah K. Adie, PharmD, and Matthew C. Konerman, MDSarah K. Adie, PharmDDepartment of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan (S.K.A.)Search for more papers by this author, and Matthew C. Konerman, MDDepartment of Internal Medicine, Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan (M.C.K.).Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M23-0588 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Sodium–glucose cotransporter-2 inhibitors (SGLT2Is) improve outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease, and heart failure (HF) with reduced ejection fraction (1). They also benefit patients with heart failure with preserved ejection fraction (HFpEF), a population often managed by hospitalists.Evidence for SGLT2Is in HFpEFThe DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) trial randomly assigned 6263 patients with HF and left ventricular ejection fraction greater than 40% to receive either 10 mg of dapagliflozin daily or placebo (1). Less than half of the patients had T2DM. The composite of ...References1. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-767. [PMID: 36041474] doi:10.1016/S0140-6736(22)01429-5 CrossrefMedlineGoogle Scholar2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 ACC/AHA/HFSA guideline for the management of heart failure. J Card Fail. 2022;28:e1-e167. [PMID: 35378257] doi:10.1016/j.cardfail.2022.02.010 CrossrefMedlineGoogle Scholar3. Honigberg MC, Vardeny O, Vaduganathan M. Practical considerations for the use of sodium-glucose co-transporter 2 inhibitors in heart failure. Circ Hear Fail. 2020;13:e006623. [PMID: 32059632] doi:10.1161/CIRCHEARTFAILURE.119.006623 CrossrefMedlineGoogle Scholar4. Das SR, Everett BM, Birtcher KK, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76:1117-1145. [PMID: 32771263] doi:10.1016/j.jacc.2020.05.037 CrossrefMedlineGoogle Scholar5. Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation. 2020;142:1040-1054. [PMID: 32673497] doi:10.1161/CIRCULATIONAHA.120.047077 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Sarah K. Adie, PharmD; Matthew C. Konerman, MDAffiliations: Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan (S.K.A.)Department of Internal Medicine, Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan (M.C.K.).Disclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-0588.Corresponding Author: Sarah K. Adie, PharmD, Department of Clinical Pharmacy, University of Michigan, Victor Vaughan Building, 1111 East Catherine Street, Room 305, Ann Arbor, MI 48109-2054; e-mail, [email protected]umich.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAnnals for Hospitalists - April 2023 David H. Wesorick Metrics Current IssueApril 2023Volume 176, Issue 4KeywordsHeart failureHospital medicineLeft ventricular ejection fraction ePublished: 18 April 2023 Issue Published: April 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...